Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00077448" target="_blank" >RIV/00023001:_____/18:00077448 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.dovepress.com/patient-reported-outcomes-in-individuals-with-hepatitis-c-virus-infect-peer-reviewed-article-PPA" target="_blank" >https://www.dovepress.com/patient-reported-outcomes-in-individuals-with-hepatitis-c-virus-infect-peer-reviewed-article-PPA</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/PPA.S172732" target="_blank" >10.2147/PPA.S172732</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir

Popis výsledku v původním jazyce

People chronically infected with hepatitis C virus (HCV) have diminished patient-reported outcomes (PROs). This study aimed to compare the impact of elbasvir/grazoprevir (EBR/GZR) treatment versus sofosbuvir with pegylated interferon and ribavirin (SOF/PR) on changes in PROs: 1) during the treatment period and 2) at posttreatment follow-up. PRO data collected during the Phase III C-EDGE Head-2-Head (H2H) open-label study was analyzed. In this trial, patients infected with HCV were randomized 1: 1 to receive either EBR/GZR or SOF/PR for 12 weeks. Patients self-administered the Short Form-36 version 2 Health Survey Acute (1-week recall) Form and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale at baseline, during treatment, and posttreatment. Between-group differences in mean change of PRO scores from baseline were estimated during the treatment period and also at the posttreatment follow-up. There were 255 patients (99.2% White, 54.1% female, 74.9% treatment naive) included in the analysis. During the treatment period, significant declines in SF-36v2 scores were observed across all domains for the SOF/PR group. Compared to the SOF/PR group, the EBR/GZR group reported more improvement in scores across all SF-36v2 domain scores at the end of the treatment period. At treatment week 12, the between-group differences for 6 out of the 8 domain scores for these patients reflected at least moderate effects (effect sizes.0.5). No significant between-group differences in change in SF-36v2 scores from baseline were detected posttreatment. The decline in SF-36v2 scores observed during the treatment period for the SOF/PR group returned to near baseline scores or above posttreatment. Treatment with EBR/GZR did not impact fatigue scores, but treatment with SOF/PR led to increased fatigue scores during treatment which resolved by posttreatment follow-up week 12. This study demonstrated that HCV treatment with EBR/GZR resulted in a significantly better PRO profile.

Název v anglickém jazyce

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir

Popis výsledku anglicky

People chronically infected with hepatitis C virus (HCV) have diminished patient-reported outcomes (PROs). This study aimed to compare the impact of elbasvir/grazoprevir (EBR/GZR) treatment versus sofosbuvir with pegylated interferon and ribavirin (SOF/PR) on changes in PROs: 1) during the treatment period and 2) at posttreatment follow-up. PRO data collected during the Phase III C-EDGE Head-2-Head (H2H) open-label study was analyzed. In this trial, patients infected with HCV were randomized 1: 1 to receive either EBR/GZR or SOF/PR for 12 weeks. Patients self-administered the Short Form-36 version 2 Health Survey Acute (1-week recall) Form and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale at baseline, during treatment, and posttreatment. Between-group differences in mean change of PRO scores from baseline were estimated during the treatment period and also at the posttreatment follow-up. There were 255 patients (99.2% White, 54.1% female, 74.9% treatment naive) included in the analysis. During the treatment period, significant declines in SF-36v2 scores were observed across all domains for the SOF/PR group. Compared to the SOF/PR group, the EBR/GZR group reported more improvement in scores across all SF-36v2 domain scores at the end of the treatment period. At treatment week 12, the between-group differences for 6 out of the 8 domain scores for these patients reflected at least moderate effects (effect sizes.0.5). No significant between-group differences in change in SF-36v2 scores from baseline were detected posttreatment. The decline in SF-36v2 scores observed during the treatment period for the SOF/PR group returned to near baseline scores or above posttreatment. Treatment with EBR/GZR did not impact fatigue scores, but treatment with SOF/PR led to increased fatigue scores during treatment which resolved by posttreatment follow-up week 12. This study demonstrated that HCV treatment with EBR/GZR resulted in a significantly better PRO profile.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Patient preference and adherence [online]

ISSN

1177-889X

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

8

Strana od-do

2631-2638

Kód UT WoS článku

000452763300002

EID výsledku v databázi Scopus

2-s2.0-85058683292